Environmental, social, and governance (ESG) programs have become a material strategic priority for pharmaceutical companies. Institutional investors, regulators, and healthcare customers increasingly evaluate pharma companies on their ESG performance alongside financial results. Employee attraction and retention is influenced by perceptions of corporate purpose and sustainability commitment. And the regulatory landscape around ESG disclosure continues to evolve, with the SEC and international counterparts establishing new requirements for climate-related and other ESG disclosures.
For pharma CEOs, ESG represents a domain where genuine strategic leadership is required but where the operational execution spans dozens of functions across the enterprise. The challenge is building a delegation framework that keeps the CEO authentically engaged in ESG as a strategic priority without making the CEO a bottleneck in the complex reporting and compliance machinery that ESG programs require.
The Strategic Importance of CEO Ownership in ESG
Before addressing delegation, it is worth being direct about one thing: ESG programs that are perceived as CEO-endorsed versus those perceived as driven solely by the sustainability function perform differently with investors, employees, and other stakeholders. CEO authenticity and personal commitment to ESG priorities is itself a material input to program effectiveness.
This means that the delegation framework for ESG cannot simply hand off the entire function to a Chief Sustainability Officer and consider the task done. The CEO needs to maintain genuine engagement with ESG priorities, even as the operational management is appropriately delegated.
The balance to achieve is a CEO who sets and owns the strategic ESG ambitions, communicates ESG commitments externally with credibility, holds the organization accountable for ESG performance, and is genuinely informed about material ESG risks and opportunities, while delegating the program management, data collection, reporting, and operational execution to a dedicated ESG function and cross-functional teams.
Defining the ESG Delegation Architecture
CEO-level ownership
The CEO retains ownership of: setting the company’s ESG ambitions and public commitments (net-zero targets, access-to-medicine goals, diversity and inclusion commitments), approving the annual ESG report and major external ESG communications, engaging with major institutional investors on ESG topics, and ensuring that ESG considerations are integrated into strategic planning and capital allocation.
These responsibilities are genuinely strategic and reflect the CEO’s personal leadership commitment. They cannot be effectively delegated without undermining the credibility of the program.
Chief Sustainability Officer or VP of ESG
The dedicated ESG function owns the design and operation of ESG programs, including the data infrastructure for ESG reporting, the management of third-party ESG ratings and assessments, the development and tracking of ESG targets and key performance indicators, the coordination of cross-functional ESG initiatives, and the production of the annual ESG report and regulatory disclosures.
The CSO or VP of ESG should have direct CEO access and should present to the board (or its relevant committee) on ESG performance. This reporting line signals the organizational priority of ESG and gives the CSO the authority needed to drive cross-functional accountability.
Cross-functional ESG owners
Most ESG activities are executed by operational functions, not the central sustainability team. Environmental sustainability (energy, water, waste, carbon emissions) is owned by facilities, manufacturing, and supply chain. Social programs (patient access, diversity and inclusion, community engagement) are owned by commercial, HR, and corporate affairs. Governance programs are owned by legal, compliance, and the board secretariat.
The delegation framework should specify cross-functional ESG owners for each major program area, with clear accountability for hitting targets and providing data to the central ESG function.
Environmental Sustainability: Delegation in Practice
For a pharmaceutical manufacturing company, environmental performance is often the most operationally complex ESG domain. Manufacturing facilities, supply chain operations, and R&D activities generate significant carbon emissions, water use, and waste streams.
The CEO should set the environmental ambitions (net-zero target year, renewable energy commitment, water reduction goals) and hold senior operational leaders accountable for progress. The operational execution, including capital investments in energy efficiency, renewable energy procurement, and waste reduction programs, belongs to the facilities and manufacturing organizations.
The CEO should receive a quarterly environmental performance dashboard and should review annual environmental targets during the strategic planning process. Between those touchpoints, the environmental sustainability programs should operate without CEO involvement in specific initiatives.
Social Programs: Delegating While Maintaining Authentic Voice
The social dimension of pharma ESG often includes patient access programs, pricing and affordability commitments, diversity and inclusion targets, and community investment. These programs touch on topics where the CEO’s authentic voice is particularly important, creating the risk of CEO over-involvement in programs that should be executed by commercial, medical affairs, and HR.
The delegation principle in social ESG programs is that the CEO defines the commitment and the standards for how the company behaves, while operational leaders own the execution. For patient access, the CEO should set the policy (for example, committing that the company will provide access programs for patients who cannot afford a product) while the commercial and medical affairs teams own the design and operation of those programs.
For diversity and inclusion, the CEO should set aspirational targets and model the behaviors the company values, while the HR and talent management functions own the people processes, data tracking, and programmatic interventions.
The CEO’s engagement in social programs should be focused on external communications (articulating the company’s commitments and reporting progress publicly), senior accountability reviews (holding the executive team accountable for D&I targets and patient access program performance), and personal modeling (demonstrating inclusive leadership behaviors and engaging with patient communities directly).
Governance: The Board’s Primary Domain
The governance dimension of ESG is primarily a board-level responsibility, with the CEO operating as the principal liaison between management and the board. Governance programs, including board composition and independence, executive compensation practices, compliance and ethics programs, and shareholder engagement, are driven by the board and its relevant committees.
The CEO’s delegation role in governance ESG is to ensure that management is providing the board with the information it needs to exercise governance oversight effectively, and that the compliance and legal functions are operating the governance infrastructure that generates ESG governance performance.
Managing ESG Ratings and Investor Relations
Institutional investors increasingly use ESG ratings from agencies such as MSCI, Sustainalytics, and ISS to inform investment and engagement decisions. Improving the company’s ESG ratings is partly a matter of improving actual performance and partly a matter of ensuring that the data and disclosures that rating agencies use are accurate and comprehensive.
The operational management of ESG ratings and investor ESG engagement should be delegated to the CSO working in close coordination with the investor relations function. This includes responding to rating agency questionnaires, engaging with investors on ESG inquiries, and preparing for annual proxy season ESG discussions.
The CEO should be directly involved in major ESG investor engagements, including one-on-one meetings with the ESG teams of large institutional investors and participation in ESG-focused investor day presentations. These interactions are relationship and strategic communications investments that the CEO is uniquely positioned to make.
Climate Risk and Regulatory Disclosure
The SEC’s climate disclosure rule and international equivalents such as IFRS S2 have elevated climate risk as a disclosure and governance matter with direct CEO accountability. Pharma CEOs should understand that climate-related financial risk disclosure is no longer purely a sustainability function matter; it is a financial reporting and corporate governance matter.
The delegation framework for climate disclosure should be coordinated between the sustainability function (which owns the underlying data and scenarios analysis), the finance function (which integrates climate risk into financial reporting processes), and legal and compliance (which reviews disclosure language for regulatory compliance).
The CEO and CFO are jointly accountable for the accuracy of climate-related disclosures. This means the CEO should be actively engaged in reviewing climate disclosure content before it is filed, even if the technical analysis is delegated to the sustainability and finance teams.
For broader context on how pharma CEOs approach strategic delegation, the R&D delegation framework addresses parallel governance principles in the scientific domain. For guidance on delegating the regulatory dimensions of ESG-related compliance programs, the regulatory affairs guide is a useful complement.
Building ESG into the Executive Performance Management System
One of the most powerful levers for ensuring that ESG delegation actually produces organizational accountability is integrating ESG performance into executive compensation. When ESG targets are included in the annual incentive plans for the CEO’s direct reports, those leaders have a structured accountability mechanism that reinforces the delegation framework.
Pharma CEOs should work with the compensation committee of the board to ensure that a meaningful portion of variable compensation for at least the CEO, CSO, and relevant operational leaders is linked to ESG performance targets. The specific metrics should be material, measurable, and strategically relevant (for example, carbon emissions reduction, access-to-medicine program enrollment, or D&I representation at senior levels).
Practical Governance Calendar for ESG
An effective ESG governance calendar for pharma CEOs includes:
Monthly: ESG performance dashboard review by the CSO (15 to 20 minutes, flagging metrics off-track and emerging regulatory developments).
Quarterly: Cross-functional ESG performance review (60 minutes, covering all ESG pillars, with relevant functional leaders present).
Semi-annually: ESG investor engagement planning (coordination between CSO and IR on upcoming ESG meetings and proxy season preparation).
Annually: ESG strategy and target-setting review, ESG report review and approval, board ESG committee presentation.
This calendar gives the CEO appropriate visibility into ESG performance without requiring continuous involvement in program execution.
Conclusion
ESG and sustainability programs represent a strategic domain where pharma CEO leadership genuinely matters and where effective delegation is essential. By combining authentic personal ownership of the strategic commitments and external narrative with a robust delegation framework for operational execution, pharma CEOs can build ESG programs that generate real organizational performance and stakeholder credibility. The key is building the right structure, the right leadership team, and the right governance calendar, and then trusting the team to execute with the accountability that the framework establishes.
Related Reading
For further context, explore Delegation Framework for the 3PL Provider CEO and Delegation Framework for Academic Medical Center CEO.